Regulatory T cells exhibit differential therapeutic effects across tissues during chronic autoimmune inflammation
Clicks: 5
ID: 330052
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #45 of 47 articles by views in international immunology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Current therapies for autoimmune diseases rely largely on non-specific immunosuppression, which can lead to adverse effects such as malignancy and severe infections. Treg-based therapies have therefore attracted attention as a more targeted approach, particularly in preventive or early-stage settings. However, their efficacy after disease onset, especially in chronic inflammation, remains poorly established. Furthermore, it remains unclear whether Treg therapy exerts uniform therapeutic effects across tissues within the same individual. Here, we demonstrate that Tregs retain therapeutic potential in chronic autoimmune inflammation, but their efficacy differs between tissues. Using a TCR-retrogenic mouse model, in which monoclonal autoreactive CD4+ T cells drive spontaneous chronic dermatitis and arthritis, polyclonal Treg administration effectively resolved chronic dermatitis but only limited disease progression in chronic arthritis. Despite these differences in outcomes, transferred Tregs were detected in local tissues and draining lymph nodes, suggesting that tissue-specific environments may underlie differential therapeutic responsiveness. To investigate the basis of this difference, we performed microarray and GSVA-based pathway analyses. Under untreated conditions, skin and joint tissues exhibited distinct baseline pathway activity patterns, with the skin showing higher activity of the Hippo signaling pathway, a growth-regulatory pathway, and the joints displaying stronger enrichment of inflammation-related pathways, including complement- and angiogenesis-associated pathways. Following Treg administration, skin-but not joint-tissue showed pathway modulation, including increased Wnt and decreased IL-17 signaling pathway activity, consistent with a more reparative environment. These findings indicate that distinct inflammatory environments underlie differential responsiveness to Treg therapy across tissues, highlighting their context-dependent therapeutic potential in chronic autoimmune inflammation.
| Reference Key |
openalex_W7214654434
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yuji Nishimura, Yosuke Nagahata, Daiya Ohara, Koji Terada, Yuka Kobayashi, Yasutoshi Agata, Keiji Hirota, Hiroshi Kawamoto |
| Journal | international immunology |
| Year | 2026 |
| DOI |
10.1093/intimm/dxag051
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.